JP2018505205A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505205A5 JP2018505205A5 JP2017542401A JP2017542401A JP2018505205A5 JP 2018505205 A5 JP2018505205 A5 JP 2018505205A5 JP 2017542401 A JP2017542401 A JP 2017542401A JP 2017542401 A JP2017542401 A JP 2017542401A JP 2018505205 A5 JP2018505205 A5 JP 2018505205A5
- Authority
- JP
- Japan
- Prior art keywords
- isolating
- pharmaceutically acceptable
- acceptable salt
- disorder
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WFVZVMGMPBTVBW-VYRBHSGPSA-N CC(C)(C)OC(N(CCC1)[C@@H]1C(c(cc1)c(CCO)cc1F)O)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1C(c(cc1)c(CCO)cc1F)O)=O WFVZVMGMPBTVBW-VYRBHSGPSA-N 0.000 description 1
- WFVZVMGMPBTVBW-AAFJCEBUSA-N CC(C)(C)OC(N(CCC1)[C@H]1C(c(cc1)c(CCO)cc1F)O)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@H]1C(c(cc1)c(CCO)cc1F)O)=O WFVZVMGMPBTVBW-AAFJCEBUSA-N 0.000 description 1
- MVUVVOWTNVWEFT-PZORYLMUSA-N [O-][NH+](CCC1)[C@H]1C1OCCc2c1ccc(F)c2 Chemical compound [O-][NH+](CCC1)[C@H]1C1OCCc2c1ccc(F)c2 MVUVVOWTNVWEFT-PZORYLMUSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115064P | 2015-02-11 | 2015-02-11 | |
| US62/115,064 | 2015-02-11 | ||
| PCT/US2016/017539 WO2016130796A1 (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020018081A Division JP7023994B2 (ja) | 2015-02-11 | 2020-02-05 | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505205A JP2018505205A (ja) | 2018-02-22 |
| JP2018505205A5 true JP2018505205A5 (enExample) | 2019-03-22 |
| JP6657241B2 JP6657241B2 (ja) | 2020-03-04 |
Family
ID=55456908
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542401A Expired - Fee Related JP6657241B2 (ja) | 2015-02-11 | 2016-02-11 | Ｃｎｓ疾患を治療するための１−複素環イソクロマニル化合物およびアナログ |
| JP2020018081A Expired - Fee Related JP7023994B2 (ja) | 2015-02-11 | 2020-02-05 | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ |
| JP2022018580A Pending JP2022065050A (ja) | 2015-02-11 | 2022-02-09 | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020018081A Expired - Fee Related JP7023994B2 (ja) | 2015-02-11 | 2020-02-05 | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ |
| JP2022018580A Pending JP2022065050A (ja) | 2015-02-11 | 2022-02-09 | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9856238B2 (enExample) |
| EP (2) | EP4046995B1 (enExample) |
| JP (3) | JP6657241B2 (enExample) |
| KR (1) | KR102601972B1 (enExample) |
| CN (2) | CN111925360B (enExample) |
| AU (1) | AU2016219253C1 (enExample) |
| CA (1) | CA2976095C (enExample) |
| CY (1) | CY1125198T1 (enExample) |
| DK (1) | DK3256466T3 (enExample) |
| EA (1) | EA201791804A1 (enExample) |
| ES (2) | ES2967643T3 (enExample) |
| HU (1) | HUE058698T2 (enExample) |
| IL (1) | IL253914B (enExample) |
| MX (2) | MX371404B (enExample) |
| MY (1) | MY188160A (enExample) |
| NZ (1) | NZ735011A (enExample) |
| PH (1) | PH12017501422A1 (enExample) |
| PL (1) | PL3256466T3 (enExample) |
| PT (1) | PT3256466T (enExample) |
| SG (2) | SG10201806809QA (enExample) |
| UA (1) | UA122222C2 (enExample) |
| WO (1) | WO2016130796A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016219253C1 (en) * | 2015-02-11 | 2022-12-08 | Pgi Drug Discovery Llc | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders |
| CA2976092A1 (en) * | 2015-02-11 | 2016-08-18 | Sunovion Pharmaceuticals Inc. | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
| MX2019000982A (es) | 2016-07-29 | 2019-07-04 | Sunovion Pharmaceuticals Inc | Compuestos y composiciones y usos de los mismos. |
| EA201990400A1 (ru) | 2016-07-29 | 2019-07-31 | Суновион Фармасьютикалз, Инк. | Соединения и композиции и их применение |
| IL271464B2 (en) | 2017-06-30 | 2024-08-01 | Chase Therapeutics Corp | NK-1 antagonist compositions and methods for use in the treatment of depression |
| JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CN113784755B (zh) | 2019-03-14 | 2024-05-10 | 赛诺维信制药公司 | 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 |
| US12077546B2 (en) | 2021-04-10 | 2024-09-03 | Sumitomo Pharma Co., Ltd. | Bicyclic pyridine derivative |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| US5238939A (en) * | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
| IE73232B1 (en) * | 1990-05-25 | 1997-05-21 | Akzo Nv | Isochromane derivatives |
| DE69912279T2 (de) | 1998-06-30 | 2004-07-29 | Eli Lilly And Co., Indianapolis | 5-ht1f agonisten |
| SE9902267D0 (sv) | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| EP1446396A1 (en) * | 2001-11-08 | 2004-08-18 | Sepracor, Inc. | Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram |
| JP4738418B2 (ja) * | 2004-12-21 | 2011-08-03 | エフ．ホフマン−ラ ロシュ アーゲー | クロマン誘導体及びｃｎｓ障害の処置におけるその使用 |
| JP2008538576A (ja) | 2005-04-22 | 2008-10-30 | ワイス | クロマンおよびクロメン誘導体およびその使用 |
| JP2009524618A (ja) * | 2006-01-27 | 2009-07-02 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ障害の処置における２−イミダゾールの使用 |
| KR101103118B1 (ko) | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| PT3252057T (pt) | 2009-12-04 | 2024-06-04 | Sunovion Pharmaceuticals Inc | Compostos multicíclicos e métodos de utilização dos mesmos |
| JP5715713B2 (ja) | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| AR090557A1 (es) | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
| AU2013369649B2 (en) * | 2012-12-31 | 2018-07-26 | Sunovion Pharmaceuticals Inc. | Heterocyclic compounds and methods of use thereof |
| AU2016219253C1 (en) * | 2015-02-11 | 2022-12-08 | Pgi Drug Discovery Llc | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders |
-
2016
- 2016-02-11 AU AU2016219253A patent/AU2016219253C1/en not_active Ceased
- 2016-02-11 PL PL16708262T patent/PL3256466T3/pl unknown
- 2016-02-11 DK DK16708262.7T patent/DK3256466T3/da active
- 2016-02-11 UA UAA201708945A patent/UA122222C2/uk unknown
- 2016-02-11 MX MX2017010363A patent/MX371404B/es active IP Right Grant
- 2016-02-11 HU HUE16708262A patent/HUE058698T2/hu unknown
- 2016-02-11 SG SG10201806809QA patent/SG10201806809QA/en unknown
- 2016-02-11 NZ NZ735011A patent/NZ735011A/en not_active IP Right Cessation
- 2016-02-11 MX MX2020001157A patent/MX392664B/es unknown
- 2016-02-11 EA EA201791804A patent/EA201791804A1/ru unknown
- 2016-02-11 EP EP22166538.3A patent/EP4046995B1/en active Active
- 2016-02-11 MY MYPI2017702923A patent/MY188160A/en unknown
- 2016-02-11 ES ES22166538T patent/ES2967643T3/es active Active
- 2016-02-11 KR KR1020177025290A patent/KR102601972B1/ko active Active
- 2016-02-11 WO PCT/US2016/017539 patent/WO2016130796A1/en not_active Ceased
- 2016-02-11 CA CA2976095A patent/CA2976095C/en active Active
- 2016-02-11 EP EP16708262.7A patent/EP3256466B9/en active Active
- 2016-02-11 CN CN202010607608.6A patent/CN111925360B/zh not_active Expired - Fee Related
- 2016-02-11 PT PT167082627T patent/PT3256466T/pt unknown
- 2016-02-11 ES ES16708262T patent/ES2911910T3/es active Active
- 2016-02-11 SG SG11201706515QA patent/SG11201706515QA/en unknown
- 2016-02-11 CN CN201680018639.XA patent/CN107531674B/zh not_active Expired - Fee Related
- 2016-02-11 JP JP2017542401A patent/JP6657241B2/ja not_active Expired - Fee Related
- 2016-02-11 US US15/041,852 patent/US9856238B2/en not_active Expired - Fee Related
-
2017
- 2017-08-08 IL IL253914A patent/IL253914B/en unknown
- 2017-08-09 PH PH12017501422A patent/PH12017501422A1/en unknown
- 2017-11-21 US US15/819,372 patent/US10336732B2/en active Active
-
2019
- 2019-05-06 US US16/403,698 patent/US11192885B2/en not_active Expired - Fee Related
-
2020
- 2020-02-05 JP JP2020018081A patent/JP7023994B2/ja not_active Expired - Fee Related
-
2021
- 2021-10-29 US US17/452,786 patent/US20220185799A1/en not_active Abandoned
-
2022
- 2022-02-09 JP JP2022018580A patent/JP2022065050A/ja active Pending
- 2022-05-20 CY CY20221100352T patent/CY1125198T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018193405A5 (enExample) | ||
| JP7541594B2 (ja) | ＰＩ３Ｋ－γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 | |
| JP2018505204A5 (enExample) | ||
| CN104487441B (zh) | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 | |
| JP2022043078A5 (enExample) | ||
| CA2836410C (en) | Tyrosine kinase inhibitors | |
| JP2013032389A5 (enExample) | ||
| JP2016512563A5 (enExample) | ||
| CN106456652A (zh) | Btk抑制剂的盐和固体形式 | |
| JP2018158926A (ja) | ブルトン型チロシンキナーゼの阻害剤 | |
| JP2019048806A5 (enExample) | ||
| JP2010520264A5 (enExample) | ||
| JP2012521994A5 (enExample) | ||
| JP2019505541A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2014528485A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2014512451A5 (enExample) | ||
| JP2015536307A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| CN103502249A (zh) | 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物 | |
| JP2012519182A5 (enExample) | ||
| JP2013522275A5 (enExample) | ||
| JP2016540749A5 (enExample) | ||
| CN106715413B (zh) | 作为肝x受体调节剂的哌嗪衍生物 |